CYTK
Price
$47.77
Change
-$1.24 (-2.53%)
Updated
Dec 17, 04:59 PM (EDT)
64 days until earnings call
DSGN
Price
$6.24
Change
-$0.05 (-0.79%)
Updated
Dec 17, 04:59 PM (EDT)
78 days until earnings call
Ad is loading...

CYTK vs DSGN

Header iconCYTK vs DSGN Comparison
Open Charts CYTK vs DSGNBanner chart's image
Cytokinetics
Price$47.77
Change-$1.24 (-2.53%)
Volume$21.74K
CapitalizationN/A
Design Therapeutics
Price$6.24
Change-$0.05 (-0.79%)
Volume$1.62K
CapitalizationN/A
CYTK vs DSGN Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DSGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. DSGN commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and DSGN is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (CYTK: $47.78 vs. DSGN: $6.25)
Brand notoriety: CYTK and DSGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 117% vs. DSGN: 170%
Market capitalization -- CYTK: $5.64B vs. DSGN: $353.88M
CYTK [@Biotechnology] is valued at $5.64B. DSGN’s [@Biotechnology] market capitalization is $353.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileDSGN’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • DSGN’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than DSGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 3 TA indicator(s) are bullish while DSGN’s TA Score has 3 bullish TA indicator(s).

  • CYTK’s TA Score: 3 bullish, 6 bearish.
  • DSGN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both CYTK and DSGN are a bad buy in the short-term.

Price Growth

CYTK (@Biotechnology) experienced а -5.48% price change this week, while DSGN (@Biotechnology) price change was -5.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.44%, and the average quarterly price growth was +4.25%.

Reported Earning Dates

CYTK is expected to report earnings on Feb 20, 2025.

DSGN is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($5.64B) has a higher market cap than DSGN($354M). DSGN YTD gains are higher at: 135.849 vs. CYTK (-42.772). DSGN has higher annual earnings (EBITDA): -60.23M vs. CYTK (-481.94M). CYTK has more cash in the bank: 1.01B vs. DSGN (254M). DSGN has less debt than CYTK: DSGN (2.52M) vs CYTK (790M). CYTK has higher revenues than DSGN: CYTK (3.22M) vs DSGN (0).
CYTKDSGNCYTK / DSGN
Capitalization5.64B354M1,593%
EBITDA-481.94M-60.23M800%
Gain YTD-42.772135.849-31%
P/E RatioN/AN/A-
Revenue3.22M0-
Total Cash1.01B254M398%
Total Debt790M2.52M31,324%
FUNDAMENTALS RATINGS
CYTK: Fundamental Ratings
CYTK
OUTLOOK RATING
1..100
5
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
PROFIT vs RISK RATING
1..100
48
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
57
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CYTKDSGN
RSI
ODDS (%)
Bearish Trend 6 days ago
82%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 8 days ago
88%
Declines
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 7 days ago
77%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DSGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMORX38.12-0.18
-0.47%
Patient Opportunity R
KIRYX12.68-0.06
-0.47%
Westwood Global Rl Estt Inst
JPIVX30.83-0.20
-0.64%
JPMorgan U.S. Applied Data Sci Val I
LOMGX33.30-0.39
-1.16%
Lord Abbett Growth Opportunities F3
OEGYX35.02-0.49
-1.38%
Invesco Discovery Mid Cap Growth Y

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with KRON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then KRON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-2.53%
KRON - CYTK
43%
Loosely correlated
-0.39%
IOVA - CYTK
42%
Loosely correlated
-0.38%
DARE - CYTK
42%
Loosely correlated
+0.31%
CKPT - CYTK
41%
Loosely correlated
+9.59%
DSGN - CYTK
40%
Loosely correlated
-0.64%
More

DSGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DSGN has been loosely correlated with CYTK. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DSGN jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DSGN
1D Price
Change %
DSGN100%
-0.64%
CYTK - DSGN
39%
Loosely correlated
-2.53%
MDGL - DSGN
38%
Loosely correlated
-1.58%
AGIO - DSGN
36%
Loosely correlated
-1.71%
VRDN - DSGN
35%
Loosely correlated
-3.34%
RCKT - DSGN
35%
Loosely correlated
+1.36%
More